Crossmark

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

Crossref DOI link: https://doi.org/10.1007/s10875-025-01952-5

Published Online: 2025-11-12

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lumry, William R.

Palumbo, Michael

Hsu, Connie

Hussain, Iftikhar

McNeil, Donald

Bridges, Tracy

Wedner, H. James

Scarupa, Mark

Mondou, Elsa

Nanaware-Kharade, Nisha

Hanna, Kim

Coll, Montse Querolt

Oliveras, Juan
Funding

Funding for this research was provided by:

Grifols
License Information

Text and Data Mining valid from 2025-11-12

Version of Record valid from 2025-11-12
More Information

Article History

Received: 8 January 2025

Accepted: 9 October 2025

First Online: 12 November 2025

Declarations

:

: CH, IH, DM, TB, HJW and MS report no competing interests. WL reports that his institution has received research grants from CSL Behring, KalVista, Ionis, Pharvaris and Astria. WL has received consulting fees from BioCryst. CSL Behring, Astria, KalVista, Intellia, Pharvaris, Pharming and Takeda and honoraria from Pharming, CSL Behring, Takeda and Biocryst. WL has served on advisory boards for Biocryst, CSL Behring, Astria, KalVista, Intellia, Pharvaris, Pharming, Takeda and the medical advisory board of the US Hereditary Angioedema Association. MP reports serving as a speaker for CSL Behring and serving on advisory boards for Takeda. EM, NN-K, KH, MQC, and JO are employees of Grifols.

Document is current

Any future updates will be listed below